文献速递乳腺癌

Rilvegostomig联合T-DXd用于早期乳腺癌的I-SPY2.2随机临床试验

Rilvegostomig Plus Trastuzumab-Deruxtecan for Early-Stage Breast Cancer: The I-SPY2.2 Randomized Clinical Trial.
PubMed 文献 · JAMA Oncol · 2026-10-22

I-SPY2.2试验评估了Rilvegostomig联合T-DXd(RT-DXd)作为高危早期ERBB2阴性乳腺癌初始治疗的效果与安全性。在免疫阳性肿瘤中,RT-DXd的模型病理完全缓解率(pCR)达54%,达到预设成功阈值,HR阳性/免疫阳性为57%,HR阴性/免疫阳性为52%。免疫阳性且达pCR的患者中,多数仅需A模块治疗并避免了蒽环类化疗。

要点

  • RT-DXd在免疫阳性ERBB2阴性早期乳腺癌中pCR率达54%,达到预设成功阈值。
  • 免疫阳性达pCR者中62%仅需A模块,97%避免了蒽环类化疗。
  • ILD发生率为12.4%,含1例3级事件,需系列胸部CT监测。

核心结论

  • RT-DXd在免疫阳性、ERBB2阴性早期乳腺癌中显示出有前景的抗肿瘤活性,毒性以低级别为主。
  • 与免疫阴性患者不同,许多免疫阳性且达pCR的患者避免了标准化疗(包括蒽环类),支持在生物标志物筛选人群中进一步评估。

研究设计与样本

  • II期、多中心、适应性随机新辅助试验,纳入高危II/III期ERBB2阴性早期乳腺癌(含ERBB2低/超低表达)患者。
  • 意向治疗人群中RT-DXd组105例、对照组77例可评估;参与者最多接受3个序贯治疗模块,基于反应和亚型分配。

主要发现

  • RT-DXd组A模块105例中,免疫阳性肿瘤的模型pCR率为54%,达到预设成功阈值。
  • HR阳性/免疫阳性疾病pCR率为57%,HR阴性/免疫阳性疾病为52%。
  • 跨所有治疗模块,总pCR率与对照方案相似;免疫阳性达pCR者中21例(62%)仅需A模块,33例(97%)避免了蒽环类化疗。
  • 最常见不良事件为疲乏和恶心;严重不良事件包括肺栓塞和ILD(各3/105,2.9%)。
  • ILD发生于13例(12.4%),含1例3级事件,通过系列胸部CT监测早期识别。

关键数值与推荐

  • 主要终点为病理完全缓解(pCR)。
  • 安全性评估包括不良事件,重点监测间质性肺病(ILD)。
  • 因评估2级及以上ILD,入组两次暂停,经数据安全监测委员会批准后恢复。

临床怎么用

  • 对免疫阳性、ERBB2阴性高危早期乳腺癌,RT-DXd可作为初始治疗选择,部分患者仅需A模块即可达pCR并避免蒽环类化疗。
  • 治疗期间需系列胸部CT监测ILD,关注疲乏、恶心及肺栓塞等不良事件。

局限性

  • 为II期适应性随机试验,样本量有限,意向治疗人群可评估例数少于随机例数。
  • 疗效数据在试验期间持续分析,部分分析在发表前更新。
  • 免疫阴性患者未显示类似获益,结论主要适用于生物标志物筛选人群。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: The I-SPY2.2 trial tests personalized treatment strategies to improve outcomes while reducing exposure to standard chemotherapy in patients with high-risk early breast cancer (EBC). OBJECTIVE: To evaluate the efficacy and safety of trastuzumab-deruxtecan (T-DXd), an antibody drug conjugate targeting low ERBB2 (formerly HER2) expression, combined with rilvegostomig (R), a bispecific antibody targeting programmed cell death 1 protein and T-cell immunoglobulin and ITIM domain as initial therapy in I-SPY2.2 (RT-DXd). DESIGN, SETTING, AND PARTICIPANTS: This phase 2, multicenter, adaptively randomized neoadjuvant trial enrolled patients with high-risk stage II/III ERBB2-negative EBC (including those with ERBB2 low/ultralow tumors), as stratified by hormone receptor (HR) status and response-predictive subtypes. It was conducted at 30 sites in the US; efficacy data were analyzed continuously during the trial to update probabilities and other analyses before publication. INTERVENTIONS: Participants received up to 3 sequential treatment blocks, based on response and subtype: RT-DXd (block A), taxane-based therapy with/without immunotherapy (block B), and doxorubicin-cyclophosphamide (AC) with/without immunotherapy (block C). MAIN OUTCOMES AND MEASURES: The primary end point was pathologic complete response (pCR). Safety assessments included adverse events (AEs), with focused monitoring for interstitial lung disease (ILD). RESULTS: A total of 182 individuals (mean [SD] age: RT-DXd, 48.1 [13.1] years; control, 50.9 [12.0] years) participated in the trial. Eighty-eight were randomized to the contemporary control arm, and 108 of 289 remaining participants (37%) were randomized to RT-DXd; 3 participants did not receive block A treatment, and 11 did not receive the assigned control treatment, leaving the intention-to-treat population with 105 and 77 evaluable participants. Among 105 patients treated with RT-DXd in block A, the modeled pCR rate was 54% in immune-positive tumors, which met the predefined threshold for success. Similar pCR rates were observed in HR-positive, immune-positive disease (57%) and HR-negative, immune-positive disease (52%). Across all treatment blocks, overall pCR rates were similar to control regimens; however, among immune-positive patients who experienced pCR, 21 (62%) required only block A, and 33 (97%) avoided anthracycline-based chemotherapy. Enrollment was paused twice to evaluate grade 2 or higher ILD and resumed after data safety monitoring board approval. The most common AEs were fatigue and nausea. Serious AEs included pulmonary embolism and ILD (3 of 105 [2.9%] each). ILD occurred in 13 (12.4%), including 1 grade 3 event, and was identified early with serial chest computed tomography monitoring. CONCLUSIONS AND RELEVANCE: This randomized clinical trial found that treatment with RT-DXd demonstrated promising activity, with mostly low-grade toxic effects in immune-positive, ERBB2-negative EBC. Unlike immune-negative patients, many immune-positive patients who experienced pCR avoided standard chemotherapy, including anthracyclines, supporting further evaluation in biomarker-selected populations. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT01042379.

来源:JAMA Oncol,查看原文。版权归原作者所有。

引用

  1. O'Sullivan CC, Kalinsky KM, Yau C, et al. Rilvegostomig Plus Trastuzumab-Deruxtecan for Early-Stage Breast Cancer: The I-SPY2.2 Randomized Clinical Trial. JAMA Oncol. 2026. PMID: 42911610. doi:10.1001/jamaoncol.2026.4258

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。